Gosselies, Belgium, October 23, 2015 – Univercells SA, a company that designs single-use cost-efficient bioprocess solutions to open the next chapter in biomanufacturing, today announces it has closed an equity investment of €3 million with Takeda Pharmaceutical Company Limited ('Takeda') through its strategic venture arm, Takeda Ventures, Inc. The companies will launch a development program to tailor Univercells' continuous integrated manufacturing methods and integrate them into the Takeda vaccines production platform.